Enanta Pharmaceuticals

ENTA

Market cap $407M

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial wil.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company's STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA. Details of the presentations are as foll.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside chat at The Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “.

Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeti.

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $1.05 per share a year ago.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first quarter ended December 31, 2025. “Enanta entered the year with significant momentum, advancing our leading RSV treatment portfolio with preparation for a Phase 3 study and expanding our immunology pipeline with the introduction of our.

Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026. “Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver.